280 related articles for article (PubMed ID: 36613922)
1. Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas.
González-Arriagada WA; García IE; Martínez-Flores R; Morales-Pison S; Coletta RD
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613922
[TBL] [Abstract][Full Text] [Related]
2. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer.
Weitzenfeld P; Ben-Baruch A
Cancer Lett; 2014 Sep; 352(1):36-53. PubMed ID: 24141062
[TBL] [Abstract][Full Text] [Related]
3. The chemokines CCL5 and CXCL12 exhibit high-affinity binding to N-terminal peptides of the non-cognate receptors CXCR4 and CCR5, respectively.
Kessler N; Akabayov SR; Cohen LS; Scherf T; Naider F; Anglister J
FEBS J; 2024 Feb; 291(3):458-476. PubMed ID: 37997026
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
Aldinucci D; Casagrande N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772686
[TBL] [Abstract][Full Text] [Related]
5. Co-receptor antagonists as HIV-1 entry inhibitors.
Shaheen F; Collman RG
Curr Opin Infect Dis; 2004 Feb; 17(1):7-16. PubMed ID: 15090884
[TBL] [Abstract][Full Text] [Related]
6. CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy.
Grande F; Occhiuzzi MA; Rizzuti B; Ioele G; De Luca M; Tucci P; Svicher V; Aquaro S; Garofalo A
Molecules; 2019 Feb; 24(3):. PubMed ID: 30717348
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
Seibert C; Sakmar TP
Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.
Ghezzi S; Menzo S; Brambilla A; Bordignon PP; Lorini AL; Clementi M; Poli G; Vicenzi E
Virology; 2001 Feb; 280(2):253-61. PubMed ID: 11162839
[TBL] [Abstract][Full Text] [Related]
10. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
11. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
12. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.
Kranjc MK; Novak M; Pestell RG; Lah TT
Radiol Oncol; 2019 Nov; 53(4):397-406. PubMed ID: 31747383
[TBL] [Abstract][Full Text] [Related]
13. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.
Scarlatti G; Tresoldi E; Björndal A; Fredriksson R; Colognesi C; Deng HK; Malnati MS; Plebani A; Siccardi AG; Littman DR; Fenyö EM; Lusso P
Nat Med; 1997 Nov; 3(11):1259-65. PubMed ID: 9359702
[TBL] [Abstract][Full Text] [Related]
14. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma.
Guo L; Cui ZM; Zhang J; Huang Y
Chin J Cancer; 2011 May; 30(5):336-43. PubMed ID: 21527066
[TBL] [Abstract][Full Text] [Related]
15. CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor.
Honczarenko M; Le Y; Glodek AM; Majka M; Campbell JJ; Ratajczak MZ; Silberstein LE
Blood; 2002 Oct; 100(7):2321-9. PubMed ID: 12239139
[TBL] [Abstract][Full Text] [Related]
16. The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5.
Labrecque J; Anastassov V; Lau G; Darkes M; Mosi R; Fricker SP
Assay Drug Dev Technol; 2005 Dec; 3(6):637-48. PubMed ID: 16438659
[TBL] [Abstract][Full Text] [Related]
17. CCR5 is a potential therapeutic target for cancer.
Hemmatazad H; Berger MD
Expert Opin Ther Targets; 2021 Apr; 25(4):311-327. PubMed ID: 33719836
[TBL] [Abstract][Full Text] [Related]
18. Targeting chemokine receptors for HIV: past, present and future.
Fricker SP
Future Med Chem; 2015; 7(17):2311-5. PubMed ID: 26627446
[No Abstract] [Full Text] [Related]
19. Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists.
Princen K; Hatse S; Vermeire K; De Clercq E; Schols D
Retrovirology; 2004 Mar; 1():2. PubMed ID: 15169555
[TBL] [Abstract][Full Text] [Related]
20. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
